{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23","upperLimit":"67","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"One of the secondary outcomes that will be measured is progression free survival at 1 Year.\n\nProgressive Disease (PD) is defined as a \\>25% increase in serum monoclonal paraprotein, a \\>25% increase in 24-hour urinary light chain excretion, a \\>25% increase in plasma cells in bone marrow aspirate, an increase in the size or the development of new bone lesions/soft tissue plasmacytomas, or the development of hypercalcemia.","dispersionType":"95% Confidence Interval","groups":[{"description":"Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.\n\nFludarabine/Busulfan x 4 days:\n\nFludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.\n\nBusulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.\n\nThe Fludarabine shall be administered prior to the Busulfan each day.","id":"OG000","title":"Flu-Bu4"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 Year","title":"The Percentage of Patients Free From Progression at 1 Year","type":"SECONDARY","unitOfMeasure":"percentage of patients"}